Badri served on the IPPF Board of Directors from 2008 to 2015 (and served as its president from 2013 to 2015). He was previously involved in the patient registry, R&D, and bylaws efforts.
Badri currently provides consulting services to life sciences companies. He previously served as medical affairs lead for the ASPIRE unit at Actelion Pharmaceuticals, which was acquired by Janssen/Johnson & Johnson in 2017. At Actelion, Badri served as study physician for the largest observational study in the MF variant of cutaneous T-cell lymphoma (an ultra-rare skin disease), co-led the investigator-initiated study program for ASPIRE, and oversaw an interdisciplinary effort across medical affairs, field medical, and clinical operations. He was previously a Senior Medical Director at Archimedes (healthcare modeling and analytics), Director of Business Development and Market Research at Nodality (personalized/predictive medicine), biotechnology equities analyst at Lehman Brothers, Regulatory Team Leader at Genentech, and consultant with McKinsey and Company. Badri earned an A.B. in Biology and Public Policy from Harvard University and an M.D. from Yale University.
He lives in the San Francisco area with his wife and three sons (ages 12, 9, and 6). When he has free time, he likes to exercise in the gym, play soccer, and listen to jazz.